The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …

Importance The incidence of SARS-CoV-2 infection, including among individuals who have
received 2 doses of COVID-19 vaccine, increased substantially following the emergence of …

Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) …

SARS-CoV-2 lineages, a substantially mutated sublineage of BA. 2 has recently emerged.
Designated BA. 2.86, 1 the geographic origin of this sublineage is currently unclear and, as …

The continual evolution of SARS-CoV-2 and the emergence of variants that show resistance
to vaccines and neutralizing antibodies threaten to prolong the COVID-19 pandemic …

Towards the end of 2021, SARS-CoV-2 vaccine effectiveness was threatened by the
emergence of the omicron clade (B. 1.1. 529), with more than 30 mutations in the spike …

The recent emergence of the Omicron variant has raised concerns on vaccine efficacy and
the urgent need to study more efficient vaccination strategies. Here we observed that an …

The elicited anti-SARS-CoV-2 immunity is becoming increasingly complex with individuals
receiving a different number of vaccine doses paired with or without recovery from …

(A) Differences from BA. 2 in BA. 2.75 (orange), and BA. 2.75. 2 (red, underlined), depicted
upon the SARS-CoV-2 BA. 2 receptor binding domain (pdb: 7UB0). Sensitivity of SARS-CoV …